LG completes phase 3 trial for sustained release recombinant human growth hormone

Published: 2009-06-16 06:59:00

Updated: 2009-06-16 06:59:00

LG Life Sciences Ltd., a Korean pharmaceutical manufacturer, said on June 11 that it has successfully completed phase 3, placebo-controlled six month efficacy and safety data in adults with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone.

The clinical results were presented at the 91st annual meeting of the Endocrine Society (END...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.